This study provides first evidence that IL-27 modulates immune checkpoint expression in CLL patients, specifically demonstrating increased TIM-3 expression on CD8+ T cells and modest upregulation of intracellular Gal-9. Here, HAVCR2 is linked to B-cell chronic lymphocytic leukemia.